Skip to Main Content

Paper Details

Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.
Biol Blood Marrow Transplant
27
2020
GVHD, PID, Primary Immunodeficiency Diseases, T-cell, aGVHD, acute GVHD, busulfan, chronic GVHD, cyclophosphamide, donor T cells, genetic defect, immunoglobulin, lymphoproliferative disorders, malignancies, organ toxicities, patients, pentostatin, pre-, primary immunodeficiency
Author NameAffiliation
Seth M SteinbergNational Cancer Institute, Center for Cancer Research, National Institutes of Health
Seth M SteinbergNational Cancer Institute, Center for Cancer Research, National Institutes of Health
Jeremy J RoseNational Cancer Institute, National Institutes of Health
Jeremy J RoseNational Cancer Institute, National Institutes of Health
Xiao-Yi YanNational Cancer Institute, National Institutes of Health
Xiao-Yi YanNational Cancer Institute, National Institutes of Health
William G TelfordNational Cancer Institute, National Institutes of Health
William G TelfordNational Cancer Institute, National Institutes of Health
Veena KapoorNational Cancer Institute, National Institutes of Health
Veena KapoorNational Cancer Institute, National Institutes of Health
Alexandra F FreemanLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health
Daniel H FowlerNational Cancer Institute, National Institutes of Health
Daniel H FowlerNational Cancer Institute, National Institutes of Health
Ronald E GressNational Cancer Institute, National Institutes of Health
Ronald E GressNational Cancer Institute, National Institutes of Health
  • 1 - 15

Datasets

Release 1.2